Copyright © 2021. Inderes Oyj. All rights reserved.


Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Kirjaudu sisään

Redeye increases its estimates and fair value range for Carasent. We argue that the acquisition of Avans Soma was strategically and financially sound, and we expect an accelerated Norwegian expansion, with a Webdoc launch in the neighboring country by H2’21 or early 2022. Carasent merits a premium, as it has >90% recurring revenues in a non-cyclical and steadily growing market, coupled with net retention numbers of 115-120%.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Carasent ASA is an investment management company that provides services to businesses that develop entrepreneurial and e-health solutions. The company has a system called 'Webdoc' a cloud-based medical record system with integrated add-on services for the private and public health care industry.